Logo image of AVBP

ARRIVENT BIOPHARMA INC (AVBP) Stock Fundamental Analysis

NASDAQ:AVBP - Nasdaq - US04272N1028 - Common Stock - Currency: USD

23.6  +0.08 (+0.34%)

After market: 23.6 0 (0%)

Fundamental Rating

3

Overall AVBP gets a fundamental rating of 3 out of 10. We evaluated AVBP against 559 industry peers in the Biotechnology industry. AVBP has a great financial health rating, but its profitability evaluates not so good. AVBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AVBP had negative earnings in the past year.
In the past year AVBP has reported a negative cash flow from operations.
AVBP Yearly Net Income VS EBIT VS OCF VS FCFAVBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

AVBP has a Return On Assets (-59.15%) which is comparable to the rest of the industry.
The Return On Equity of AVBP (-62.93%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -59.15%
ROE -62.93%
ROIC N/A
ROA(3y)-30.66%
ROA(5y)N/A
ROE(3y)-32.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVBP Yearly ROA, ROE, ROICAVBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVBP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVBP Yearly Profit, Operating, Gross MarginsAVBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, AVBP has more shares outstanding
There is no outstanding debt for AVBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVBP Yearly Shares OutstandingAVBP Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
AVBP Yearly Total Debt VS Total AssetsAVBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 34.12 indicates that AVBP is not in any danger for bankruptcy at the moment.
AVBP has a better Altman-Z score (34.12) than 96.42% of its industry peers.
There is no outstanding debt for AVBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.12
ROIC/WACCN/A
WACCN/A
AVBP Yearly LT Debt VS Equity VS FCFAVBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 14.34 indicates that AVBP has no problem at all paying its short term obligations.
AVBP has a better Current ratio (14.34) than 86.76% of its industry peers.
AVBP has a Quick Ratio of 14.34. This indicates that AVBP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 14.34, AVBP belongs to the best of the industry, outperforming 86.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.34
Quick Ratio 14.34
AVBP Yearly Current Assets VS Current LiabilitesAVBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

AVBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.85%.
EPS 1Y (TTM)-31.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-171.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AVBP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.89% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-32.3%
EPS Next 2Y-17.48%
EPS Next 3Y6.52%
EPS Next 5Y28.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVBP Yearly Revenue VS EstimatesAVBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
AVBP Yearly EPS VS EstimatesAVBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AVBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVBP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVBP Price Earnings VS Forward Price EarningsAVBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVBP Per share dataAVBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.48%
EPS Next 3Y6.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (6/9/2025, 4:30:01 PM)

After market: 23.6 0 (0%)

23.6

+0.08 (+0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-13 2025-08-13
Inst Owners70.84%
Inst Owner Change124.25%
Ins Owners15.2%
Ins Owner Change0%
Market Cap807.36M
Analysts87.14
Price Target40.29 (70.72%)
Short Float %19.83%
Short Ratio22.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-78.75%
Min EPS beat(2)-180.53%
Max EPS beat(2)23.03%
EPS beat(4)3
Avg EPS beat(4)-29.08%
Min EPS beat(4)-180.53%
Max EPS beat(4)40.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.55%
PT rev (3m)2.33%
EPS NQ rev (1m)1.66%
EPS NQ rev (3m)15.48%
EPS NY rev (1m)-13.97%
EPS NY rev (3m)-2.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.99
P/tB 3.99
EV/EBITDA N/A
EPS(TTM)-3.77
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.5
OCFYN/A
SpS0
BVpS5.92
TBVpS5.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.15%
ROE -62.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.66%
ROA(5y)N/A
ROE(3y)-32.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.34
Quick Ratio 14.34
Altman-Z 34.12
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-171.43%
EPS Next Y-32.3%
EPS Next 2Y-17.48%
EPS Next 3Y6.52%
EPS Next 5Y28.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.21%
EBIT Next 3Y17.03%
EBIT Next 5YN/A
FCF growth 1Y-25.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.73%
OCF growth 3YN/A
OCF growth 5YN/A